Mitral Valve Disease Market is Projected to Grow Expeditiously: to Reach $4.65 Billion by 2029

 Backed by rigorous analysis and deep industry knowledge, this study is designed to support growth and investment decisions in the mitral valve disease market.

 

 How Much Is The Mitral Valve Disease Market Worth?
 The mitral valve disease market size has grown strongly in recent years. It will grow from $3 billion in 2024 to $3.28 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to patient education initiatives, adequate reimbursement policies and insurance coverage, growing healthcare expenditure, rising awareness and screening efforts, and expanding market presence.
 
 The mitral valve disease market size is expected to see strong growth in the next few years. It will grow to $4.65 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to growing prevalence of mitral valve disease, increasing adoption for minimally invasive techniques, soaring innovations in heart valve surgery, rise venture capital investments, and rising interest of manufacturers. Major trends in the forecast period include technological advancements, advancements in transcatheter technologies, and increasing technological advancements in surgical procedures.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=16480&type=smp
 
 What Are The Current Leading Growth Drivers For Mitral Valve Disease Market?
 The increasing prevalence of vascular heart diseases is expected to propel the growth of mitral valve disease market going forward. Vascular heart diseases encompass a group of conditions affecting the blood vessels supplying the heart or within the heart itself. A complex interplay of lifestyle choices, demographic changes, medical conditions, environmental factors, and genetic variables drives the increasing cases of vascular heart diseases. Vascular heart diseases, such as ischemic heart disease and hypertension, can indirectly cause mitral valve disease by compromising the heart’s structure and function, leading to conditions that affect the mitral valve. For instance, in June 2024, according to data from the Australian Bureau of Statistics 2020–21, a National Health Survey conducted by the Australian Institute of Health and Welfare, an Australia-based government agency, in Australia, the death rate from cardiovascular disease per 100,000 population increased from 143.7 in 2021 to 148.2 in 2022 for males. Therefore, the increasing prevalence of vascular heart diseases is driving the mitral valve disease market. 
 
 Which Segment Accounted For The Largest Mitral Valve Disease Market Share?
 The mitral valve diseasemarket covered in this report is segmented — 
 
 1) By Treatment Type: Mitral Valve Repair; Mitral Valve Replacement; Cardiac Resynchronization Therapy; Mitral Valve Therapeutics
 2) By Indication: Mitral Valve Stenosis; Mitral Valve Prolapse; Mitral Valve Regurgitation
 3) By End-User: Hospitals; Ambulatory Surgical Centers; Other End-Users
 
 Subsegments:
 1) By Mitral Valve Repair: Surgical Repair; Minimally Invasive Repair; Percutaneous Mitral Valve Repair 
 2) By Mitral Valve Replacement: Mechanical Valve Replacement; Biological Valve Replacement; Transcatheter Mitral Valve Replacement (TMVR) 
 3) By Cardiac Resynchronization Therapy: Pacemaker Therapy; Implantable Cardioverter-Defibrillators (ICD); Biventricular Pacing 
 4) By Mitral Valve Therapeutics: Pharmacological Treatments; Anticoagulation Therapy; Mitral Valve Repair Devices 
 
 Mitral Valve Disease Market Emerging Trends And Opportunities
 Major companies operating in the mitral valve disease market are developing stented tissue valves to address the growing demand for minimally invasive treatment options. Stented tissue valves are designed to provide durable and reliable performance, offering patients an alternative to traditional surgical interventions. For instance, in April 2024, Medtronic, an Ireland-based healthcare company, launched the Avalus Ultra valve, an advanced surgical aortic tissue valve designed for enhanced ease of use during implantation and long-term patient management. Building on a decade of clinical experience with the original Avalus valve, the Avalus Ultra features a low valve profile for easier implantation, a PEEK base frame for consistent circularity, and an industry-leading Effective Orifice Area (EOA) that may promote greater blood flow. Additionally, it includes a radiopaque coil for clear visibility during future valve-in-valve procedures. 
 
 Which Are The Top Companies To Hold The Market Share In Mitral Valve Disease Market?
 Major companies operating in the mitral valve disease market are Pfizer Inc., Bayer AG, Abbott Laboratories, Novartis AG, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences, ShockWave Medical Inc., Artivion Inc., TTK Health Care Limited, Braile Biomedica, JenaValve Technology Inc., 4C Medical technologies, Labcor Laboratorios Ltda, CryoLife Inc., Valcare Medical, Affluent Medical, Colibri Heart Valve LLC, Coramaze Technologies, Corcym UK Limited, HighLife Medical, Micro International Devices Inc., Neovasc Inc., Mitralign Inc., Transcatheter Technologies GmbH
 
 View the full mitral valve disease market report here:
 https://www.thebusinessresearchcompany.com/report/mitral-valve-disease-global-market-report
 
 Which Region Is Projected To Account For The Largest Share Of The Mitral Valve Disease Market?
 Europe was the largest region in the mitral valve disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mitral valve disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company